<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00630045</url>
  </required_header>
  <id_info>
    <org_study_id>OXALIC</org_study_id>
    <nct_id>NCT00630045</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis</brief_title>
  <official_title>A Phase III Study of Surgery in Combination With Neoadjuvant Chemotherapy of Oxaliplatin Plus Capecitabine in Colorectal Cancer With Respectable Liver Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to discuss the efficacy and safety of neoadjuvant chemotherapy with XELOX
      regimen (oxaliplatin plus capecitabine) .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liver metastasis is the most important prognostic factor of colorectal cancer. Reasonable
      multidisciplinary therapy might improve the prognosis of patients with liver metastasis.
      Surgery has been the first choice under such situation. Recently, neoadjuvant chemotherapy
      has also shown its value in unresectable liver metastasis, for it can increase the chance of
      R0 resection and give some clues to chemosensitivity of agents. However, for those resectable
      lesions, the role and safety of neoadjuvant chemotherapy has yet to be confirmed. so we
      design this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease free survival rate</measure>
    <time_frame>3 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>at the time of pathological report</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival rate and over survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>surgery related mortality</measure>
    <time_frame>peri-operation period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate and safety of XELOX as a neoadjuvant regimen</measure>
    <time_frame>no time frame</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">392</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Resectable Liver Metastasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2~3 cycles of neoadjuvant chemotherapy before resection of liver metastasis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>no neoadjuvant chemotherapy, resect the liver metastasis directly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neoadjuvant chemotherapy with oxaliplatin and capecitabine</intervention_name>
    <description>oxaliplatin: 130mg/m2, d1(Q3w) capecitabine:1000mg/m2 bid, d1-14(Q3w)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>resection of liver metastasis</intervention_name>
    <description>surgery with the aim of R0 resection</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed colorectal cancer with liver metastasis(all patients should
             have the pathological report of colorectal cancer. The chances of hepatocellular
             carcinoma or metastasis from other primary lesions should be excluded. )

          2. Liver metastasis should be resected with R0 resection and to save enough normal liver
             tissue

          3. Anticipated liver resection: for normal liver, ﹤70%; for liver with cirrhosis, ﹤50%

          4. No metastasis of other organs or lymph nodes in abdominal cavity

          5. No previous use of oxaliplatin and capecitabine, or previous adjuvant treatment ended
             more than 6 months

          6. Age 18 to 75 years old

          7. Karnofsky performance status ≥70

          8. Life expectancy of ≥3 month

          9. Bilirubin level &lt; 1.5mg/dL

         10. Serum creatinine &lt;1.0 times ULN

         11. Absolute neutrophil count ≥2000/mm3, platelet&gt;100,000/mm3, Hb&gt;9g/dl

         12. Having signed informed consent

        Exclusion Criteria:

          1. previous use of oxaliplatin or fluorouracil-based chemotherapy in 6 months.

          2. No R0 resection or not enough normal liver tissue left

          3. previous radiotherapy of target lesions

          4. accompanied with unresectable other metastasis or malignant pleural fluids or ascites.

          5. complete or uncompleted liver obstruction

          6. peripheral neuropathy(NCI-CTC grade 1 or more)

          7. mental disturbance neuropathy that influence the cognition, including brain metastasis

          8. other serious disease such as uncontrollable active infection, heart infarction with 1
             year, un controlled hypertension, arrhythmia with high risk, or unstable heart
             infarction,heart failure, coronary artery disease, myocardial infarction within the
             last 6 months

          9. Other previous malignancy within 5 year, except non-melanoma skin cancer

         10. accompany with other anti-tumor therapies,including immune therapy, intervention or
             injection with chemotherapeutical agents into serous cavity, or participating other
             clinical trials.

         11. Pregnancy or lactation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shan Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital, Department of General Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lin Shen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University, School of Oncology, Department of GI Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>zhou jing, MD</last_name>
    <phone>86-10-66583821</phone>
    <email>zhoujing58@sohu.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaotian Zhang, MD</last_name>
    <phone>86-10-88196561</phone>
    <email>zhangxt@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University, School of Oncology</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100036</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaotian Zhang, MD</last_name>
      <phone>86-10-88196561</phone>
      <email>zhangxt@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>jifang gong, MD</last_name>
      <phone>86-10-88196088</phone>
      <email>goodjf@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Peking University, People's Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jing zhou, MD</last_name>
      <phone>86-10-66583821</phone>
      <email>zhoujing58@sohu.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2008</study_first_posted>
  <last_update_submitted>March 5, 2008</last_update_submitted>
  <last_update_submitted_qc>March 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2008</last_update_posted>
  <responsible_party>
    <name_title>Yeying Jiang/Associate professor</name_title>
    <organization>Peking University People's Hospital,Department of General Surgery</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

